News

V-Bio Ventures leads Camel-IDS EUR 37m Series A financing to develop cancer targeted radiopharmaceuticals

November 15th, 2018|V-Bio News|

V-Bio Ventures participates in 22.5 million euros series B financing round of HORAMA

September 18th, 2018|V-Bio News|

Syndesi Therapeutics announces appointment of experienced management team to lead development of novel pro-cognitive SV2A modulators

March 1st, 2018|Portfolio News|

V-Bio Ventures invests in UCB spinout Syndesi Therapeutics to develop novel therapeutics for cognitive disorders

February 1st, 2018|V-Bio News|

Confo Therapeutics enters into drug discovery collaboration with Roche

December 19th, 2017|Portfolio News|

OCTIMET Oncology NV awarded €1.12 million grant from VLAIO

November 7th, 2017|Portfolio News|

Confo Therapeutics enters into drug discovery collaboration with Lundbeck

September 26th, 2017|Portfolio News|

Octimet: Dosing of First Patient with investigational agent OMO-1

August 25th, 2017|Portfolio News|

V-Bio Ventures leads EUR 7.7M financing of Aphea.Bio

June 16th, 2017|V-Bio News|

V-Bio Ventures invests in OCTIMET Oncology

January 19th, 2017|V-Bio News|

Oxular Appoints David Fellows as Chairman of the Board

January 11th, 2017|Portfolio News|

V-Bio Ventures closes first life sciences fund, raising over € 75 million

December 1st, 2016|V-Bio News|

Confo Therapeutics appoints Dr. Cedric Ververken as Chief Executive Officer

September 6th, 2016|Portfolio News|

Precision Ocular Ltd Completes £15.5 million Series A Financing V-Bio Ventures joins investment syndicate

July 19th, 2016|Portfolio News|

Confo Therapeutics appoints Dr Christel Menet as Chief Scientific Officer

May 10th, 2016|Portfolio News|

V-Bio Ventures invests in VIB spinout Confo Therapeutics NV

February 2nd, 2016|V-Bio News|

First Closing of V-Bio Ventures Fund 1 with commitments of € 63 million

November 19th, 2015|V-Bio News|